Biosimulation Market Size, Share, Growth, Trends, Consumption, Revenue, Company Analysis, Regional Insights and Forecast 2021-2030

Published Date : Nov 2020 | No. of Pages : 200 Pages | Category : Healthcare

The global biosimulation market size surpassed US$ 2.1 Bn in 2020 and expected to reach over US$ 7 billion by 2030.

Biosimulation can be defined as computer-aided mathematical simulation of biological processes, which form an integral part of the human biology system. Biosimulation is focused on offering model-based prediction of the behavior and the dynamics of biological systems. The growth of the global biosimulation market can be attributed to significant rise in spending on R&D by pharmaceutical and biotechnology companies. Additionally, high cost associated with re-conducting clinical trials, owing to the high failure rate in phase III clinical trials contributes to the adoption of biosimulation in drug discovery and drug development, which, in turn, boosts the growth of the market.

North America dominated the global biosimulation market in terms of revenue in 2019 and the trend is projected to continue during the forecast period. The market in the region is anticipated to expand at a high CAGR from 2020 to 2030. The growth of the market in North America can be attributed to the strong recommendation by the U.S. FDA for adopting biosimulation, increase in adoption of predictive biosimulation in the R&D process, and rise in focus on the development of biosimulation platforms for the development of COVID-19 vaccines.

Strategic Acquisitions among Key Market Players

Leading players, such as Certara and Simulations Plus, focus on enhancing their market presence by adopting inorganic growth strategies. This, in turn, will enable them to cater the rise in demand and consolidate their position in the biosimulation market. Simulations Plus, a leading player in the biosimulation market acquired Lixoft of Paris, France, in April 2020. Lixoft is focused on designing software solutions for reducing the cost and increasing the success rate of new drug development.

In February 2020, Certara acquired the modelling and biosimulation technology assets from In Silico Biosciences, Inc. The assets acquired include platform of multiple integrated quantitative systems pharmacology (QSP) modules related to brain pathology and physiology.

Software Dominated Global Market

In terms of offering type, the software segment is projected to account for major share of the global biosimulation market during the forecast period. The growth of the segment can be attributed to increase in the number of pharmaceutical and biotechnology companies, regulatory agencies, and academic & research institutes employing biosimulation software during the research process of drug discovery and drug development.

Segmentation

  • The global biosimulation market has been segmented based on offering type, application, end user, and region
  • In terms of offering type, the global biosimulation market has been categorized into software and services. The software segment has been split into PK/PD modeling & simulation, PBPK modeling & simulation, trial simulators, molecular modeling, and others.
  • Based on application, the global biosimulation market has been classified into drug discovery, drug development, and others. The drug discovery segment has been segregated into target identification & validation and lead identification & optimization.
  • Rise in usage of biosimulation and modeling technologies in drug discovery can be attributed to increase in usage of molecular modelling for the identification of effective compounds that help enhance the efficiency and reduce drug toxicity. Furthermore, role of molecular dynamics simulation in drug discovery propels the segment. The drug development segment has been bifurcated into pre-clinical testing and clinical trial.
  • In terms of end user, the global biosimulation market has been divided into contract research organization, pharmaceutical & biotechnology companies, research institutes, regulatory institutes, and others

Prominent Regions

The global biosimulation market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global biosimulation market in 2019. The U.S. was a major market for biosimulation in the region in 2019. The expansion of the market in the country can be attributed to the presence of leading players, rise in usage of biosimulation technology by pharmaceutical and biotechnology companies, and recommendation of regulatory agencies to employ the biosimulation technology in the drug development process.

The biosimulation market in Asia Pacific is expected to expand at a high CAGR from 2020 to 2030 driven by developing countries such as China and India. Life science research is gaining momentum in countries across Asia, partly due to favorable government policies and high demand for innovative drugs. Additionally, a large and trained talent pool of researchers and engineers coupled with significant computational infrastructure have ensured that the expansion remains at a relatively rapid pace. Furthermore, the biosimulation market is expanding rapidly in China and India despite late entry of industry players in these countries.

Strategic Acquisitions and Partnerships by Key Players to Propel Global Market

The global biosimulation market is fragmented in terms of number of players. Key players operating in the global biosimulation market are Certara, Dassault Systèmes S.A., Schrödinger, Inc., Simulations Plus, Inc., Rhenovia Pharma, Advanced Chemistry Development, Inc., Insilico Biotechnology AG, Physiomics plc, Genedata AG, and Rosa & Co. LLC., among others.

Global Biosimulation Market: Segmentation

  • Biosimulation Market, by Offering Type
  • Software
    • PK/PD Modeling & Simulation
    • PBPK Modeling & Simulation
    • Trial Simulators
    • Molecular Modeling
    • Others
    • Services
  • Biosimulation Market, by Application
    • Drug Discovery
      • Target Identification & Validation
      • Lead Identification & Optimization
    • Drug Development
      • Pre-clinical Testing
      • Clinical Trial
    • Others
  • Biosimulation Market, by End User
    • Contract Research Organization
    • Pharmaceutical & Biotechnology Companies
    • Research Institutes
    • Regulatory Institutes
    • Others
  • Biosimulation Market, by Region
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Scope of the Report

VRR’s report on the global biosimulation market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global biosimulation market from 2016 to 2030, considering 2020 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global biosimulation market for the forecast period.

The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with market leaders and opinion makers. Secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global biosimulation market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the global biosimulation market.

The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competition dynamics in the global biosimulation market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global biosimulation market. The next section of the report highlights the USPs, which include technological advancements, healthcare industry overview, key industry events, and COVID-19 pandemic impact on industry (value chain and short/mid/long-term impact) in the global biosimulation market.

The report delves into the competition landscape of the global biosimulation market. Key players operating in the global biosimulation market have been identified and each one of these has been profiled for its distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global biosimulation market report.

Key Questions Answered in Biosimulation Market Report

  1. What will be the sales revenue generated by biosimulation across all regions during the forecast period?
  2. What are the key trends in the global biosimulation market?
  3. What are major drivers, restraints, and opportunities in the global biosimulation market?
  4. Which regional market is set to expand at the fastest CAGR during the forecast period?
  5. Which application segment will generate the maximum revenue by 2030 and which product segment will expand at the fastest CAGR during the forecast period?

Research Objectives and Research Approach

The comprehensive report on the global biosimulation market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and health care compliances laid down by accredited agencies in the purview of research in the global biosimulation market. It is followed by market introduction, market dynamics, and an overview of the global biosimulation market, which includes TMR’s analysis of market drivers, restraints, and trends affecting the market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key players in the global biosimulation market has been mapped to ascertain the size of the market in terms of value. The forecast presented here assesses the total revenue generated in the global biosimulation market. In order to provide an accurate forecast, we initiated by sizing up the current biosimulation market with the help of the parent market.

The report analyzes the global biosimulation market in terms of offering type, application, end user, and region. Key segments under each criteria have been studied at length and the market share of each of these by the end of 2030 has been provided. These valuable insights would help stakeholders in making informed business decisions for investments in the global biosimulation market.

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biosimulation Market

4. Market Overview

    4.1. Definition

    4.2. Market Indicators

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Biosimulation Market Value (US$ Mn) Forecast, 2018–2030

    4.5. Global Biosimulation Market Outlook

5. Key Insights

    5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.2. Technological Advancements

    5.3. Healthcare Industry Overview

    5.4. Key Industry Events

6. Global Biosimulation Market Analysis and Forecast, by Offering Type

    6.1. Introduction

    6.2. Global Biosimulation Market Value Share Analysis, by Offering Type

    6.3. Global Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        6.3.1. Software

            6.3.1.1. PK/PD Modeling & Simulation

            6.3.1.2. PBPK Modeling & Simulation

            6.3.1.3. Trial Simulators

            6.3.1.4. Molecular Modeling

            6.3.1.5. Others

        6.3.2. Services

    6.4. Global Biosimulation Market Attractiveness Analysis, by Offering Type

7. Global Biosimulation Market Analysis and Forecast, by Application

    7.1. Introduction

    7.2. Global Biosimulation Market Value Share Analysis, by Application

    7.3. Global Biosimulation Market Value Forecast, by Application, 2018–2030

        7.3.1. Drug Discovery

            7.3.1.1. Target Identification & Validation

            7.3.1.2. Lead Identification & Optimization

        7.3.2. Drug Development

            7.3.2.1. Pre-clinical Testing

            7.3.2.2. Clinical Trial

        7.3.3. Others

    7.4. Global Biosimulation Market Attractiveness Analysis, by Application

8. Global Biosimulation Market Analysis and Forecast, by End-user

    8.1. Introduction

    8.2. Global Biosimulation Market Value Share Analysis, by End-user

    8.3. Global Biosimulation Market Value Forecast, by End-user, 2018–2030

        8.3.1. Contract Research Organization

        8.3.2. Pharmaceutical & Biotechnology Companies

        8.3.3. Research Institutes

        8.3.4. Regulatory Institutes

        8.3.5. Others

    8.4. Global Biosimulation Market Attractiveness Analysis, by Application

9. Global Biosimulation Market Analysis and Forecast, by Region

    9.1. Regional Outlook

    9.2. Introduction

    9.3. Global Biosimulation Market Value Forecast, by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

    9.4.  Global Biosimulation Market Attractiveness Analysis, by Region

10. North America Biosimulation Market Analysis and Forecast

    10.1.  Key Findings

    10.2.  North America Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        10.2.1. Software

            10.2.1.1. PK/PD Modeling & Simulation

            10.2.1.2. PBPK Modeling & Simulation

            10.2.1.3. Trial Simulators

            10.2.1.4. Molecular Modeling

            10.2.1.5. Others

        10.2.2. Services

    10.3. North America Biosimulation Market Value Forecast, by Application, 2018–2030

        10.3.1. Drug Discovery

            10.3.1.1. Target Identification & Validation

            10.3.1.2. Lead Identification & Optimization

        10.3.2. Drug Development

            10.3.2.1. Pre-clinical Testing

            10.3.2.2. Clinical Trial

        10.3.3. Others

    10.4. North America Biosimulation Market Value Forecast, by End-user, 2018–2030

        10.4.1. Contract Research Organization

        10.4.2. Pharmaceutical & Biotechnology Companies

        10.4.3. Research Institutes

        10.4.4. Regulatory Institutes

        10.4.5. Others

    10.5. North America Biosimulation Market Value Forecast, by Country, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Biosimulation Market Attractiveness Analysis

        10.6.1. By Offering Type

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Biosimulation Market Analysis and Forecast

    11.1.  Key Findings

    11.2.  Europe Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        11.2.1. Software

            11.2.1.1. PK/PD Modeling & Simulation

            11.2.1.2. PBPK Modeling & Simulation

            11.2.1.3. Trial Simulators

            11.2.1.4. Molecular Modeling

            11.2.1.5. Others

        11.2.2. Services

    11.3. Europe Biosimulation Market Value Forecast, by Application, 2018–2030

        11.3.1. Drug Discovery

            11.3.1.1. Target Identification & Validation

            11.3.1.2. Lead Identification & Optimization

        11.3.2. Drug Development

            11.3.2.1. Pre-clinical Testing

            11.3.2.2. Clinical Trial

        11.3.3. Others

    11.4. Europe Biosimulation Market Value Forecast, by End-user, 2018–2030

        11.4.1. Contract Research Organization

        11.4.2. Pharmaceutical & Biotechnology Companies

        11.4.3. Research Institutes

        11.4.4. Regulatory Institutes

        11.4.5. Others

    11.5. Europe Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        11.5.1. U.K.

        11.5.2. Germany

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Europe Biosimulation Market Attractiveness Analysis

        11.6.1. By Product

        11.6.2. By Material

        11.6.3. By Application

        11.6.4. By Distribution Channel

        11.6.5. By Country/Sub-region

12. Asia Pacific Biosimulation Market Analysis and Forecast

    12.1.  Key Findings

    12.2. Asia Pacific Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        12.2.1. Software

            12.2.1.1. PK/PD Modeling & Simulation

            12.2.1.2. PBPK Modeling & Simulation

            12.2.1.3. Trial Simulators

            12.2.1.4. Molecular Modeling

            12.2.1.5. Others

        12.2.2. Services

    12.3. Asia Pacific Biosimulation Market Value Forecast, by Application, 2018–2030

        12.3.1. Drug Discovery

            12.3.1.1. Target Identification & Validation

            12.3.1.2. Lead Identification & Optimization

        12.3.2. Drug Development

            12.3.2.1. Pre-clinical Testing

            12.3.2.2. Clinical Trial

        12.3.3. Others

    12.4. Asia Pacific Biosimulation Market Value Forecast, by End-user, 2018–2030

        12.4.1. Contract Research Organization

        12.4.2. Pharmaceutical & Biotechnology Companies

        12.4.3. Research Institutes

        12.4.4. Regulatory Institutes

        12.4.5. Others

        12.4.6.

    12.5. Asia Pacific Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        12.5.1. China

        12.5.2. India

        12.5.3. Japan

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Biosimulation Market Attractiveness Analysis

        12.6.1. By Offering Type

        12.6.2. By Application

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Biosimulation Market Analysis and Forecast

    13.1.  Key Findings

    13.2. Latin America Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        13.2.1. Software

            13.2.1.1. PK/PD Modeling & Simulation

            13.2.1.2. PBPK Modeling & Simulation

            13.2.1.3. Trial Simulators

            13.2.1.4. Molecular Modeling

            13.2.1.5. Others

        13.2.2. Services

    13.3. Latin America Biosimulation Market Value Forecast, by Application, 2018–2030

        13.3.1. Drug Discovery

            13.3.1.1. Target Identification & Validation

            13.3.1.2. Lead Identification & Optimization

        13.3.2. Drug Development

            13.3.2.1. Pre-clinical Testing

            13.3.2.2. Clinical Trial

        13.3.3. Others

    13.4. Latin America Biosimulation Market Value Forecast, by End-user, 2018–2030

        13.4.1. Contract Research Organization

        13.4.2. Pharmaceutical & Biotechnology Companies

        13.4.3. Research Institutes

        13.4.4. Regulatory Institutes

        13.4.5. Others

    13.5. Latin America Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Biosimulation Market Attractiveness Analysis

        13.6.1. By Offering Type

        13.6.2. By Application

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Biosimulation Market Analysis and Forecast

    14.1.  Key Findings

    14.2. Middle East & Africa Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        14.2.1. Software

            14.2.1.1. PK/PD Modeling & Simulation

            14.2.1.2. PBPK Modeling & Simulation

            14.2.1.3. Trial Simulators

            14.2.1.4. Molecular Modeling

            14.2.1.5. Others

        14.2.2. Services

    14.3. Middle East & Africa Biosimulation Market Value Forecast, by Application, 2018–2030

        14.3.1. Drug Discovery

            14.3.1.1. Target Identification & Validation

            14.3.1.2. Lead Identification & Optimization

        14.3.2. Drug Development

            14.3.2.1. Pre-clinical Testing

            14.3.2.2. Clinical Trial

        14.3.3. Others

    14.4. Middle East & Africa Biosimulation Market Value Forecast, by End-user, 2018–2030

        14.4.1. Contract Research Organization

        14.4.2. Pharmaceutical & Biotechnology Companies

        14.4.3. Research Institutes

        14.4.4. Regulatory Institutes

        14.4.5. Others

    14.5. Middle East & Africa Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Biosimulation Market Attractiveness Analysis

        14.6.1. By Offering Type

        14.6.2. By Application

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1.  Market Player - Competition Matrix (by tier and size of companies)

    15.2.  Market Ranking Analysis, by Company, 2019

    15.3. Company Profiles

        15.3.1. Certara

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. Dassault Systèmes S.A.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Schrödinger, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. Simulations Plus, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. Rhenovia Pharma

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Advanced Chemistry Development, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Insilico Biotechnology AG

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. Strategic Overview

            15.3.7.5. SWOT Analysis

        15.3.8. Physiomics plc

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. Genedata AG

            15.3.9.1.  Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

        15.3.10. Rosa & Co. LLC.

            15.3.10.1.  Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. Strategic Overview

            15.3.10.5. SWOT Analysis


Featured Research Reports

  • Featured Research Reports

    Women’s Digital Health Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...
  • Featured Research Reports

    Intravascular Ultrasound Devices Market (By Product: IVUS Consoles and IVUS Catheters; By Application, By End User: Hospitals, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2030

    Read more...
  • Featured Research Reports

    Intravascular Ultrasound Devices Market (By Product: IVUS Consoles and IVUS Catheters; By Application, By End User: Hospitals, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2030

    Read more...
  • Featured Research Reports

    Minimally Invasive Surgery Market (By Procedure, Disorder Type, End User: Hospitals, Ambulatory Surgical Centers, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2028

    Read more...
  • Featured Research Reports

    Minimally Invasive Surgery Market (By Procedure, Disorder Type, End User: Hospitals, Ambulatory Surgical Centers, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2028

    Read more...